XILIO THERAPEUTICS INC (XLO)
Institutional ownership reported to the SEC as of Q2 2026, across 19 quarters.
Institutions report 3,619,385 shares against 5,782,511 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end. Share count carried from an earlier filing (cy2026q1i).
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | $6.4M | 664,021 | 0.38% | 2q | HELD |
| GILEAD SCIENCES, INC. | $6.2M | 650,389 | 0.38% | 7q | HELD |
| ORBIMED ADVISORS LLC | $5.7M | 592,300 | 0.11% | new | NEW |
| Stonepine Capital Management, LLC | $4.3M | 451,988 | 1.11% | 2q | +604.4%+$3.7M |
| Frazier Life Sciences Management, L.P. | $4.0M | 422,505 | 0.09% | 2q | HELD |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | 178,517 | 0.00% | 2q | +44.4%+$525.5K |
| Sio Capital Management, LLC | $1.5M | 152,464 | 0.24% | 2q | HELD |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.1M | 111,541 | 0.00% | new | NEW |
| Merck & Co., Inc. | $1.0M | 105,982 | 0.19% | 2q | HELD |
| RENAISSANCE TECHNOLOGIES LLC | $614.6K | 64,153 | 0.00% | 2q | +29.4%+$139.7K |
| MORGAN STANLEY | $545.6K | 56,954 | 0.00% | 2q | -0.9%-$5.2K |
| GEODE CAPITAL MANAGEMENT, LLC | $374.2K | 39,055 | 0.00% | 2q | +5.0%+$17.8K |
| CITADEL ADVISORS LLC | $248.6K | 25,950 | 0.00% | new | NEW |
| VANGUARD FIDUCIARY TRUST CO | $216.5K | 22,594 | 0.00% | 2q | -20.7%-$56.3K |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $168.1K | 17,544 | 0.00% | new | NEW |
| TWO SIGMA INVESTMENTS, LP | $139.3K | 14,544 | 0.00% | new | NEW |
| Velan Capital Investment Management LP | $136.8K | 14,285 | 0.08% | 2q | HELD |
| STATE STREET CORP | $127.5K | 13,311 | 0.00% | 2q | HELD |
| PRELUDE CAPITAL MANAGEMENT, LLC | $111.1K | 11,600 | 0.01% | new | NEW |
| BlackRock, Inc. | $83.9K | 8,757 | 0.00% | new | NEW |
| Steward Partners Investment Advisory, LLC | $6.8K | 714 | 0.00% | new | NEW |
| BARCLAYS PLC | $1.1K | 115 | 0.00% | new | NEW |
| Key Financial Inc | $565 | 59 | 0.00% | 2q | HELD |
| JONES FINANCIAL COMPANIES LLLP | $262 | 29 | 0.00% | new | NEW |
| UBS Group AG | $134 | 14 | 0.00% | 2q | -99.7%-$38.5K |
| GSA CAPITAL PARTNERS LLP | $130 | 13,590 | 0.01% | 2q | -19.8% |
Five percent filings
Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →
| Filed | Form | Filer | % of class |
|---|---|---|---|
| 2026-08-14 | 13G/A | StemPoint Capital LPwith 2 co-filers | 9.5% |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 25 | $34.7M | 3,619,385 | 10 | 4 | 3 | 0.0% |
| Q1 2026 | 23 | $21.9M | 2,602,535 | 19 | 0 | 1 | 0.0% |
| Q4 2025 | 35 | $25.3M | 39,547,963 | 10 | 4 | 5 | 0.0% |
| Q3 2025 | 35 | $18.6M | 22,027,180 | 3 | 6 | 4 | 0.0% |
| Q2 2025 | 35 | $16.2M | 23,795,263 | 5 | 4 | 11 | 0.0% |
| Q1 2025 | 35 | $16.3M | 22,528,206 | 6 | 8 | 7 | 0.0% |
| Q4 2024 | 35 | $24.7M | 25,855,355 | 4 | 6 | 5 | 0.0% |
| Q3 2024 | 33 | $12.6M | 15,953,020 | 5 | 8 | 4 | 0.0% |
| Q2 2024 | 31 | $13.7M | 14,508,882 | 7 | 9 | 5 | 0.0% |
| Q1 2024 | 29 | $13.7M | 12,640,777 | 6 | 3 | 5 | 0.0% |
| Q4 2023 | 30 | $8.7M | 15,885,940 | 4 | 6 | 4 | 0.0% |
| Q3 2023 | 28 | $31.6M | 14,973,751 | 2 | 3 | 6 | 0.0% |
| Q2 2023 | 29 | $39.6M | 15,115,927 | 1 | 3 | 6 | 0.0% |
| Q1 2023 | 27 | $46.6M | 14,684,178 | 4 | 6 | 1 | 0.0% |
| Q4 2022 | 20 | $33.0M | 12,265,787 | 2 | 3 | 2 | 0.0% |
| Q3 2022 | 28 | $48.3M | 16,607,031 | 3 | 2 | 9 | 0.0% |
| Q2 2022 | 29 | $52.2M | 17,881,508 | 7 | 5 | 9 | 0.0% |
| Q1 2022 | 41 | $132.7M | 18,775,939 | 2 | 8 | 13 | 0.0% |
| Q4 2021 | 42 | $303.1M | 18,992,420 | 41 | 0 | 0 | 0.0% |